CERS — Cerus Corporation

Cerus Corporation (CERS) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Product Revenue: Achieved a record $52.7 million for Q3 2025, a 15% year-over-year increase. Year-to-date product revenue reached $148.4 million, also up 15%.
• EMEA Revenue: Increased 21% year-over-year, driven by Middle Eastern platelet sales and initial shipments to Germany.
• North American Revenue: Grew 11%, led by U.S. sales.
• IFC Revenue: Rose to $3.9 million from $2.3 million year-over-year, with a volume demand increase of approximately 110%.
• Gross Profit: Reported at $28.1 million, with gross margins at 53.4%, down from 56.9% a year ago due to inflationary pressures and production costs.
• Operating Expenses: Totaled $34.4 million, up from $31.8 million in Q3 2024, with R&D expenses at $15.8 million.
• Net Loss: Essentially breakeven compared to a loss of $2.9 million in Q3 2024.
• Non-GAAP Adjusted EBITDA: Positive for the sixth consecutive quarter at $5 million.
• Cash Position: Ended Q3 with $78.5 million in cash and equivalents.

2. Strategic Updates and Business Highlights

• INTERCEPT Product Adoption: U.S. market penetration for INTERCEPT platelets increased to mid-60%, with expectations to exceed 80% in the future.
• IFC Growth: Transitioning sales from hospitals to blood centers, with a focus on kit sales, which are expected to dominate by the end of 2026.
• International Expansion: Positive developments in Germany with the INITIATE study and recommendations from the German National Blood Advisory Committee.
• Regulatory Progress: Enrollment completed for the U.S. Phase III RedeS trial, with results anticipated in late 2026. CE Mark decision for INTERCEPT RBCs delayed by at least six months.
• Product Innovation: Successful CE Mark approval for the INT200 illuminator, with U.S. PMA submission planned for mid-2026.

3. Forward Guidance and Outlook

• Full Year 2025 Product Revenue Guidance: Increased to $202 million to $204 million, up from previous guidance of $200 million to $203 million.
• IFC Sales Guidance: Revised to $16 million to $17 million, down from $16 million to $18 million due to the shift to kit sales.
• Positive Cash Flow Expectations: Anticipation of continued positive operating cash flows for the remainder of the year.

4. Bad News, Challenges, or Points of Concern

• Gross Margin Pressures: Declining gross margins due to tariffs, inflation, and increased production costs, with expectations of continued headwinds.
• Regulatory Delays: The CE Mark decision for INTERCEPT RBCs is delayed, which could impact market entry timelines.
• Operating Expense Management: While expenses were managed well in Q3, there are concerns about sustaining this level of efficiency moving into 2026.

5. Notable Q&A Insights

• Gross Margin Stability: Management acknowledged that while some headwinds (like tariffs and FX rates) are beyond their control, they are focused on growing the business and improving margins through economies of scale and the shift to kit sales.
• IFC Supply Chain: Confidence in meeting growing demand for IFC, with improvements in production capabilities and blood centers expressing interest in producing IFC.
• Shift to Kit Model: The decision to transition to a kit-based sales model was driven by market access benefits and potential gross margin improvements. This strategy is expected to enhance sales efficiency and reduce contract cycle times.

This summary encapsulates the key points from Cerus Corporation's Q3 2025 earnings call, highlighting both the positive developments and challenges faced by the company.